What the trial was testing
The trial enrolled 714 patients with kidney disease. The study was sponsored by Boehringer Ingelheim and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was initial testing (phase 2). Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
BI 690517 reduced protein in urine by up to 39% in people with chronic kidney disease.
Lancet (London, England) · 2024 · NCT05182840
These findings — that the 10 mg dose lowered protein spillage in urine, a marker of kidney damage — were published in the Lancet (London, England) and represent the headline result of the study.
Researchers tracked outcomes across 714 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with kidney disease, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This was an initial testing study and BI 690517 is not yet FDA-approved. The drug showed promise in reducing protein spillage in urine, which can indicate slowing kidney damage. About 1 in 7 people had elevated potassium levels, though most didn't need treatment for it. Ask your kidney doctor about approved medications that protect kidney function, and whether similar trials might be right for you.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open kidney disease trials
Urine Omics Predicting IO Therapy Responses in mRCC Patients
The study aims to identify urinary metabolite and protein markers that can predict anti-tumor efficacy and adverse events in subjects receiving IO-based therapies for metastatic renal cell carcinoma.
A High Protein Egg White Pudding for People With Kidney Failure (HiPE KF)
The goal of this clinical trial is to compare protein supplements in patients with kidney failure on dialysis. The main questions it aims to answer are: * To determine whether the supplementation of egg white protein pudding in a population of individuals with kidney failure on dialysis is feasible. * To determine whether egg white protein pudding supplementation improves serum albumin similar to other standard nutritional supplements. * To determine the effects of the egg white protein pudding on frailty measures, dietary intakes and analytes in the blood. Participants will receive either the egg white pudding (experimental) or control (Ensure plus) at the end of their dialysis treatments 3-days per week for 12 weeks.